President Trump attacks symptom, not disease, in prescription drug price attack

  • The Hill | by: Robert M. Goldberg |
  • 07/10/2018 12:00 AM
N/A by N/A is licensed under N/A N/A
President Trump launched a new broadside against prescription drug manufacturers yesterday, tweeting, "Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves."  

While it may be politically popular to blame drug prices for skyrocketing insurance costs, the president's claim doesn't stand up to scrutiny. Most notably, insurers don't pay list prices for the prescription drugs they put in their plan formularies.

They pay a deeply discounted rebate price negotiated by PBMs, which are middlemen between manufacturers and insurers. And these net prices have grown at less than the rate of the Consumer Price Index over recent years on a per capita basis.

Like Trump, health insurance executives also attribute rising health care costs to prescription drug prices. America’s Health Insurance Plans President Marilyn Tavenner and American Hospital Association President Rick Pollack wrote in an op-ed for The Hill: “Unjustified and unaccountable spikes in prescription drug prices are the engine of higher costs.”
 
 
 
 
Article Photo Credit: N/A by N/A is licensed under N/A N/A
Sign Up for Our Email Newsletter

RECENT NEWS

The Spreading Cancer of Counterfeit Drugs
  • CMPI
  • 10/01/2020 12:00 AM

The Spreading Cancer of Counterfeit Drugs

Just as the coronavirus mutates to survive and thrive, so to do the purveyors of counterfeit medicines -- with their high...  Read more

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

If a potential coronavirus vaccine is not affordable, too many people will not get vaccinated, says Peter Pitts, presiden...  Read more

Former FDA Associate Commissioner Says FDA Made Right Move to Authorize Convalescent Plasma

Former FDA Associate Commissioner Says FDA Made Right Move to Authorize Convalescent Plasma

Peter Pitts, President for the Center For Medicine in the Public Interest, explains why he believes the FDA authorized th...  Read more

DRUGWONKS BLOG